Why Standard POTS Treatment Fails

You probably didn't arrive here because you've never tried anything. Most of the people reading this have been through the standard POTS playbook. Salt loading. IV fluids. Compression garments. Increased water intake. Beta blockers. Maybe midodrine. Maybe fludrocortisone. Maybe all of them at the same time.

Some of those things helped a little. Some made you worse. None of them resolved the problem. And at some point you started wondering whether the issue is that the treatment isn't strong enough, or whether it's aimed at the wrong thing entirely.

You're not alone in that question. A 2024 survey of 227 POTS patients found that 99% reported ongoing symptoms despite treatment. Only 2 out of 215 were symptom-free (Boris et al., JAHA, 2024). A separate study found that POTS patients have functional impairment comparable to congestive heart failure, while their mental health scores are normal — directly contradicting the "it's anxiety" framing (Benrud-Larson et al., Mayo Clinic Proceedings, 2002).

A growing body of research from Harvard, Vanderbilt, New York Medical College, the University of British Columbia, and others explains why the standard toolkit has a ceiling.

The Standard Approach Targets the Compensation, Not the Cause

Look at the standard POTS toolkit. Beta blockers slow the heart. Salt and fluids try to increase blood volume so the heart doesn't have to work as hard. Compression squeezes blood out of the legs so there's more to circulate. Midodrine tightens vessels to raise pressure. Every one of them is aimed at the same thing: the heart rate is too high, and we need to bring it down.

The problem with this framework is that the tachycardia in POTS is not the disease. It's the body's attempt to solve one.

A 2014 study from New York Medical College demonstrated this directly. Del Pozzi and colleagues showed that during orthostatic stress, cerebral blood flow drops before the tachycardia starts, not after (Del Pozzi et al., Hypertension, 2014). The brain loses blood flow first. Then the heart rate climbs as a compensatory response, trying to push more blood upward.

That sequence changes the entire picture. If the tachycardia is the rescue response, then suppressing it with a beta blocker doesn't fix anything. It removes the compensation while leaving the upstream problem untouched.

What Each Standard Treatment Actually Does (and Doesn't Do)

The data on these interventions is thinner than you'd expect. A Vanderbilt study gave POTS patients 1 liter of IV saline and found it improved resting hemodynamics but produced zero improvement in exercise capacity (Figueroa et al., J Appl Physiol, 2014). The only RCT on compression garments showed that leg-only compression doesn't work — you need abdominal coverage to maintain stroke volume (Bourne et al., JACC, 2021). Fludrocortisone is prescribed widely but has no adequate RCT evidence in POTS. Midodrine helps in the neuropathic subtype but performed no better than placebo in hyperadrenergic POTS.

None of these are necessarily harmful in the right context. Salt helps when you're genuinely volume-depleted. A beta blocker can bridge while the underlying regulation is being fixed. Compression helps if it covers the abdomen. The problem is when any of them becomes the treatment plan, rather than a support measure while someone figures out why the regulation failed.

The Three Upstream Problems Nobody Measured

So what's actually going wrong? Three overlapping mechanisms keep showing up in the research. Standard POTS workups almost never evaluate any of them.

Cerebral autoregulation failure

Your brain has its own blood flow regulation system. It operates independently of what your arm blood pressure says, and when it's working, it keeps brain perfusion stable whether you're lying flat or standing in a grocery store line. In POTS and related conditions, this system can fail — and nobody notices because the arm cuff still reads normal.

A 2016 Harvard study found that patients with orthostatic cerebral hypoperfusion syndrome (OCHOs) had a significant drop in cerebral blood flow on standing, averaging 24% in that cohort, while their arm blood pressure and heart rate were completely normal (Novak, Frontiers in Aging Neuroscience, 2016). The cerebrovascular resistance was elevated, meaning the brain's own arterioles were constricting inappropriately.

Salt doesn't fix cerebral autoregulation. Beta blockers don't fix it. Compression garments don't fix it. None of those treatments even measure it. You need transcranial Doppler during a tilt to see it, and most POTS clinics don't use one.

Venoconstriction reflex failure

Gravity pulls blood into your legs and abdomen every time you stand. That's normal. What's supposed to happen next is a rapid sympathetic signal that squeezes the veins and pushes blood back toward the heart. Stewart's group at New York Medical College showed that in a subset of POTS patients, that signal is weak, slow, or just doesn't show up.

Critically, they showed the vessels themselves are structurally normal. When given direct pharmacological stimulation, they constricted fine. The reflex arc is the bottleneck, not the vessel wall. The signal from the brain to squeeze the veins isn't arriving with enough force or speed.

Compression garments are a mechanical workaround for this: they squeeze the veins from outside since the nervous system isn't doing it from inside. That helps symptoms. It doesn't fix the reflex.

Systrom's group at Brigham and Women's has directly measured the downstream consequence using invasive cardiopulmonary exercise testing — actual catheters in the pulmonary artery during upright exercise. In ME/CFS patients (who overlap substantially with POTS), right atrial pressure averaged 1.9 mmHg vs. 8.3 in controls (Joseph et al., Chest, 2021). In Novak and Systrom's 2024 study, preload failure was present in 16 out of 16 POTS patients who underwent iCPET (Novak et al., 2024). The heart isn't weak. There isn't enough blood coming back to fill it. And a separate RCT proved the mechanism is neurovascular — pyridostigmine (a cholinergic drug) partially restored filling pressures, confirming this is a neural signaling problem, not a structural one (Joseph et al., Chest, 2022).

CO2-driven cerebral vasoconstriction

CO2 is one of the most powerful regulators of blood vessel diameter in the brain. When it drops, the arteries constrict. Less blood gets through. A lot of POTS patients hyperventilate subtly on standing — not the dramatic, visible kind, but enough to blow off CO2 faster than metabolism produces it. That constricts the cerebral arteries. Blood flow drops. And every symptom that follows gets attributed to "the POTS" without anyone checking what CO2 was doing.

A 2024 Harvard study established that this mechanism, called hypocapnic cerebral hypoperfusion (HYCH), is the same disorder as POTS on a spectrum (Novak et al., Frontiers in Neurology, 2024). Lewis and colleagues at the University of British Columbia independently proved the CO2 mechanism by showing that experimentally lowering CO2 during orthostatic stress reduced cerebral blood flow and worsened tolerance, and that adding CO2 back reversed both effects (Lewis et al., Journal of Physiology, 2014).

No standard POTS treatment addresses CO2. Most tilt labs don't even measure it.

The Beta Blocker Problem

Beta blockers are the most commonly prescribed medication for POTS. They're also the one that creates the most confusion when they don't work — or when they make things worse and nobody can explain why.

The resting rate of the human heart with no brain input is approximately 100-120 beats per minute. Your brain uses parasympathetic output, primarily through the vagus nerve, to slow it down to a normal resting rate of 60-80. When someone with POTS stands up and their heart rate goes from 70 to 115, that's often parasympathetic withdrawal. The brakes came off. The brain released its slowing influence and the heart drifted back toward its natural rate.

Going from 70 to 140 or 150 is different. That requires active sympathetic drive. The gas pedal is being pushed.

A beta blocker blocks the gas pedal. So if your tachycardia is from parasympathetic withdrawal (brakes off), the beta blocker has limited effect on the mechanism. It may bring the rate down somewhat, and it often reduces the palpitation sensation and the anxiety that comes with it. But if the tachycardia was the only thing maintaining your cerebral perfusion, you've now removed the compensation. Brain fog can get worse. Standing tolerance can drop. And nobody connects the two because "the heart rate looks better on paper."

The research backs this up. Raj and colleagues at Vanderbilt showed that higher-dose propranolol (80 mg) actually produced worse symptom improvement than low-dose (20 mg) in POTS patients, despite achieving greater heart rate reduction (Raj et al., Circulation, 2009). Fu's group found that propranolol normalized upright heart rate to healthy control levels but quality of life didn't change at all — and standing cardiac output was significantly lower on the drug (Fu et al., Hypertension, 2011). The heart rate "looked better." The patient didn't feel better. The cardiac output dropped.

Beta blockers aren't always wrong. When the sympathetic system is genuinely in overdrive — norepinephrine flooding the circuit, blood pressure spiking on standing, that wired-and-exhausted feeling that won't shut off — a beta blocker can provide real relief. The overdrive itself causes harm. Dampening it has clinical value and patients feel the difference. But even in those hyperadrenergic presentations, something upstream is driving the adrenergic system to run that hard. The beta blocker addresses the compensatory state. It doesn't answer why the compensation exists.

The bigger issue is that the "sympathetic overactivity" framing most POTS care operates on is itself an oversimplification. The autonomic system doesn't work as a sympathetic-vs-parasympathetic toggle. It runs at least 7 functionally independent sympathetic pathways, each regulated separately by the brain. Vagal tone and sympathetic output can both be abnormal in different ways in the same patient at the same time. Saying "the sympathetic system is overactive" is like saying "the electrical system is overactive" when one circuit is tripped. You have to know which pathway, what's driving it, and what the brain's regulation of that pathway looks like before you know whether blocking it will help or hurt.

Why "Just Exercise More" Backfires

The Levine protocol, the modified CHOP protocol, and similar graded exercise programs get recommended to almost every POTS patient at some point. The idea is that cardiovascular reconditioning improves autonomic tone, and symptoms come down as fitness goes up. For some patients that's true — particularly the ones whose primary issue is deconditioning from prolonged bedrest. Exercise gives their system a reason to recalibrate, and it does.

But for a lot of patients, exercise is the thing that breaks them. Not because they're not trying. Because their brain cannot coordinate blood flow during position changes, and upright exercise is the hardest version of that challenge. You're not reconditioning a system that got weak. You're hammering a regulation system that's already failing, over and over, and then being told the problem is effort.

The Levine protocol's own community data makes this clear. 251 patients enrolled. 59% dropped out, most because they couldn't tolerate it (George et al., Heart Rhythm, 2016). 103 finished. The protocol was designed for a deconditioned heart, not a dysregulated brain. It doesn't account for patients whose cerebral autoregulation failure makes exercise the trigger rather than the treatment.

If the regulation is intact and the body just needs reconditioning, exercise works. If the regulation is broken, you have to fix the regulation first. Those are completely different clinical problems, and the standard approach treats them identically.

In our clinic, exercise isn't prescribed for global fitness. The goal is to train the neurology so it stops being the bottleneck of fitness. We dose exercise to cerebral blood flow data, monitoring CO2 with capnography in real time. If the numbers show the regulation can handle more load, we increase it. If they show it can't, we back off. The threshold is objective, not motivational. Once the brain can coordinate blood flow under load without crashing, the fitness comes back on its own. You don't need a program for that part. You need the regulation out of the way.

What Actually Needs to Change

You have to measure the right things, target the right things, and track the right things. The standard playbook doesn't do any of the three.

Measuring means transcranial Doppler during tilt to watch cerebral blood flow in real time. Capnography to track CO2. Autonomic stress testing. Oculomotor and vestibular evaluation. These tell you why the regulation is failing, not just that the heart rate went up.

Targeting means going after the upstream mechanism. Vestibular rehabilitation to recalibrate the inputs the brainstem uses for anticipatory blood flow adjustments. Cervical proprioceptive work to clean up the position data feeding the autonomic centers. Respiratory integration to stabilize CO2 without telling you to "breathe differently." Baroreceptor reflex retraining through graded postural challenges. Endothelial support when the vessels themselves are damaged.

Tracking means transcranial Doppler before and after. Not "do you feel better today" but "did the cerebral blood flow numbers actually change." That's the difference between a treatment strategy and a guess.

Dr. Keiser is a board-certified chiropractic neurologist (DC, DACNB, FABBIR), not a medical doctor (MD/DO). This content is for educational purposes and does not constitute medical advice. It is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult a qualified healthcare provider about your specific situation. Medication decisions should be made with your prescribing physician.

← Back to Blog